Tesaro

Tesaro is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts. Tesaro is known for developing and commercializing novel cancer therapeutics with a focus on solid tumors.

History

Tesaro was founded in March 2010 by Lonnie Moulder and Mary Lynne Hedley, two former executives of MGI Pharma. The company was established with the goal of developing and commercializing novel cancer therapeutics. In 2017, Tesaro was acquired by GlaxoSmithKline (GSK), a British multinational pharmaceutical company, for $5.1 billion.

Products

Tesaro's flagship product is niraparib, a PARP inhibitor used for the treatment of ovarian cancer. Niraparib, marketed under the brand name Zejula, was approved by the U.S. Food and Drug Administration (FDA) in 2017. The company also developed rolapitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting.

Research and Development

Tesaro's research and development efforts are primarily focused on the discovery and development of new treatments for cancer. The company's pipeline includes a number of investigational drugs in various stages of clinical development, including additional PARP inhibitors and immune-oncology therapies.

See Also

• Oncology
• Biopharmaceutical
• GlaxoSmithKline
• PARP inhibitor

   This article is a pharmacology-related stub. You can help WikiMD by expanding it!